Xiaoming Yang, M.D., Professor, Chairman of the Board, China National Biotec Group Company Limited (CNBG) 

He holds MD degree in Clinical medicine and MSc degree in Microbiology and Immunology. He started his career at Lanzhou Institute of Biological Products and worked as research fellow at the Japan NIH, the U.S. FDA, and the U.S. NIH. With more than 30 years experiences in the biological industry, he has accumulated rich experiences in life sciences research, production of biological products and operation management of biological enterprises. 

He has been serving as the Chairman of the Board at CNBG since Mar. 2015. He orchestrates the corporate strategy, governs the high-level operations and integrates the internal and external resources to promote the organic growth and expansion of the company. Before his current position, he was the Chief Engineer of Sinopharm that led the R&D strategy planning and implementation and provided professional guidance and expert views for R&D projects to Sinopharm companies. He served as the President of the China National Biotec Group Company Limited (CNBG) from 2010 to 2013. 

He specializes in microbiology, immunology, molecular biology and biopreparatics. He is the Chief Scientist of vaccine program of National High-tech R&D Program (863 Program) and Director of National Institute of Vaccine Development.